Devabhaktuni Madhuri, Bangalore Sripal
Department of Medicine, Division of Cardiology, St Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Vasc Health Risk Manag. 2009;5(1):377-87. doi: 10.2147/vhrm.s3339.
Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition. Data have shown that even relatively small reductions in both blood pressure and cholesterol levels can lead to large reductions in the risk for cardiovascular events. However, though there are robust data on the beneficial effect of concomitant reduction in these risk factors, the reality is that this is achieved in <10% of patients. There is nonadherence with prescribed therapies with up to 50% of patients stopping their medications of their own volition for a variety of reasons. There is a reasonable evidence base to suggest that simplifying drug regimens and reducing pill burden will enhance patient adherence. The fixed-dose combination containing the antihypertensive agent amlodipine besylate and the statin atorvastatin is the first combination of its kind, which is both efficacious and safe and could potentially improve medication compliance, thereby improving the outcomes in these patients.
高血压和血脂异常是两种最常见的并存心血管危险因素，它们共同导致冠心病相关事件增加，这种增加不仅仅是每种疾病预期事件发生率的简单相加。数据表明，即使血压和胆固醇水平相对小幅降低，也能大幅降低心血管事件风险。然而，尽管有充分数据证明同时降低这些危险因素有益，但实际情况是，只有不到10%的患者做到了这一点。高达50%的患者因各种原因自行停药，不遵守规定治疗。有合理的证据基础表明，简化药物治疗方案和减轻服药负担将提高患者依从性。含有抗高血压药物苯磺酸氨氯地平和他汀类药物阿托伐他汀的固定剂量复方制剂是同类中的首个复方制剂，它既有效又安全，有可能提高用药依从性，从而改善这些患者的治疗效果。
